All News

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among nonsmokers, highlighting the need for broader public health strategies.

Popular artificial intelligence (AI) model GPT-4 answered 88% of questions correctly on a standardized patient safety exam.

A robust antibody response was found in patients in residents of long-term care facilities who were given the respiratory syncytial virus (RSV) vaccine.

The National Association of Accountable Care Organizations (NAACOS) September 2024 report outlined data integration, high-value culture, team-based clinical interventions, and more to enhance value-based care.

A recent data analysis draws correlations between nurses’ experience of insomnia and presenteeism, and the impact these factors have on patient care.

The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.

As hurricane season approaches, doctors, pharmacists, and clinics prepare for treating their patients when accessibility is limited.

Arash Mostaghimi, MD, MPA, MPH, director of the inpatient dermatology consult service at Brigham & Women's Hospital, discusses the utility of deuruxolitinib for treating moderate to severe alopecia areata (AA).

NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

The South Asian Healthcare Leadership Forum marked its 10th anniversary with a gathering of over 100 prominent physicians, policy makers, and executives at Brigham and Women’s Hospital.

Catalyst for Payment Reform (CPR) explores stakeholder perspectives in Florida, Michigan, and Nevada, revealing both the challenges and opportunities states face in reforming health care pricing structures.

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.

Hospitals that better utilized heart failure guideline-directed medical therapy (GDMT) had better patient outcomes, with lower mortality rates and costs.

The House of Representatives unanimously passed the bipartisan Seniors’ Access to Critical Medications Act (HR 5526), which would reverse CMS restrictions on mail delivery of cancer medications to Medicare beneficiaries.

Many patients struggle with therapeutic control, adverse effects, and costs of psoriasis treatments, prompting a renewed focus on alternative treatments like phototherapy.

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although the former may provide an edge on quality of life.

More than half of healthy term infants born in the United States are infected with respiratory syncytial virus (RSV) during their first year of life, with significant hospitalization and illness rates observed.

The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate receptor alpha–positive (FRα+), platinum-resistant epithelial ovarian cancer.

Health plans would see savings faster if they switched to etranacogene dezaparvovec sooner, the investigators found.

A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.

A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.

Strategies for integrated delivery networks (IDNs) to manage rising biologic medication costs while ensuring financial sustainability and patient outcomes are discussed during an interview with Elie M. Bahou, PharmD, MBA, senior vice president and system chief pharmacy officer at Providence.

A RAND study explores innovative approaches to alleviate stress, enhance mental health support, and address financial challenges faced by caregivers of military and veteran populations.

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Semaglutide treatment significantly improved quality of life and reduced flare-ups in patients with obesity and hidradenitis suppurativa.

Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit managers (PBMs) could affect the future of pharmaceuticals and oncology.

Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events.